FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912757866> ?p ?o ?g. }

• W2912757866 abstract "Dopaminergic pathway is the most disrupted pathway in the pathogenesis of Parkinson’s disease. Several studies reported associations of dopaminergic genes with the occurrence of adverse events of dopaminergic treatment. However, none of these studies adopted a pathway based approach. The aim of this study was to comprehensively evaluate the influence of selected single nucleotide polymorphisms of key dopaminergic pathway genes on the occurrence of motor and non-motor adverse events of dopaminergic treatment in Parkinson's disease. In total, 231 Parkinson’s disease patients were enrolled. Demographic and clinical data were collected. Genotyping was performed for 16 single nucleotide polymorphisms from key dopaminergic pathway genes. Logistic and Cox regression analyses were used for evaluation. Results were adjusted for significant clinical data. We observed that carriers of at least one COMT rs165815 C allele had lower odds for developing visual hallucinations (OR=0.34; 95%CI=0.16-0.72; p=0.004), while carriers of at least one DRD3 rs6280 C allele and CC homozygotes had higher odds for this adverse event (OR=1.88; 95%CI=1.00-3.54; p=0.049 and OR=3.31; 95%CI=1.37-8.03; p=0.008, respectively). Carriers of at least one DDC rs921451 C allele and CT heterozygotes had higher odds for orthostatic hypotension (OR=1.86; 95%CI=1.07-3.23; p=0.028 and OR=2.30; 95%CI=1.26-4.20; p=0.007, respectively). Heterozygotes for DDC rs3837091 and SLC22A1 rs628031 AA carriers also had higher odds for orthostatic hypotension (OR=1.94; 95%CI=1.07-3.51; p=0.028 and OR=2.57; 95%CI=1.11-5.95; p=0.028, respectively). Carriers of the SLC22A1 rs628031 AA genotype had higher odds for peripheral edema and impulse control disorders (OR=4.00; 95%CI=1.62-9.88; p=0.003 and OR=3.16; 95%CI=1.03-9.72; p=0.045, respectively). Finally, heterozygotes for SLC22A1 rs628031 and carriers of at least one SLC22A1 rs628031 A allele had lower odds for dyskinesia (OR=0.48; 95%CI=0.24-0.98, p=0.043 and OR=0.48; 95%CI=0.25-0.92; p=0.027, respectively). Gene-gene interactions, more specifically DDC-COMT, SLC18A2-SV2C, and SLC18A2-SLC6A3, also significantly influenced the occurrence of some adverse events. Additionally, haplotypes of COMT and SLC6A3 were associated with the occurrence of visual hallucinations (AT vs. GC: OR=0.34; 95%CI=0.16-0.72; p=0.005) and orthostatic hypotension (ATG vs. ACG: OR=2.48; 95%CI: 1.01-6.07; p=0.047), respectively. Pathway based approach allowed us to identify new potential candidates for predictive biomarkers of adverse events of dopaminergic treatment in Parkinson’s disease, which could contribute to treatment personalization." @default.
• W2912757866 created "2019-02-21" @default.
• W2912757866 creator A5022579723 @default.
• W2912757866 creator A5051874580 @default.
• W2912757866 creator A5058233829 @default.
• W2912757866 creator A5068534236 @default.
• W2912757866 creator A5070028463 @default.
• W2912757866 creator A5083598360 @default.
• W2912757866 creator A5085177497 @default.
• W2912757866 creator A5012298648 @default.
• W2912757866 date "2019-01-28" @default.
• W2912757866 modified "2023-10-16" @default.
• W2912757866 title "Dopaminergic Pathway Genes Influence Adverse Events Related to Dopaminergic Treatment in Parkinson's Disease" @default.
• W2912757866 cites W1537665479 @default.
• W2912757866 cites W1764815628 @default.
• W2912757866 cites W1965033221 @default.
• W2912757866 cites W1966257984 @default.
• W2912757866 cites W1969860509 @default.
• W2912757866 cites W1973301117 @default.
• W2912757866 cites W1977982289 @default.
• W2912757866 cites W1986602207 @default.
• W2912757866 cites W1997945197 @default.
• W2912757866 cites W2006655736 @default.
• W2912757866 cites W2009028781 @default.
• W2912757866 cites W2009299369 @default.
• W2912757866 cites W2024131851 @default.
• W2912757866 cites W2064073780 @default.
• W2912757866 cites W2074470089 @default.
• W2912757866 cites W2081643224 @default.
• W2912757866 cites W2081809584 @default.
• W2912757866 cites W2083884569 @default.
• W2912757866 cites W2089085990 @default.
• W2912757866 cites W2104155452 @default.
• W2912757866 cites W2106350754 @default.
• W2912757866 cites W2107626226 @default.
• W2912757866 cites W2109814284 @default.
• W2912757866 cites W2110730012 @default.
• W2912757866 cites W2116255206 @default.
• W2912757866 cites W2122732537 @default.
• W2912757866 cites W2149478507 @default.
• W2912757866 cites W2151578735 @default.
• W2912757866 cites W2166485700 @default.
• W2912757866 cites W2168715864 @default.
• W2912757866 cites W2169802060 @default.
• W2912757866 cites W2323466234 @default.
• W2912757866 cites W2413519360 @default.
• W2912757866 cites W2444534019 @default.
• W2912757866 cites W2518670053 @default.
• W2912757866 cites W2536951549 @default.
• W2912757866 cites W2560555363 @default.
• W2912757866 cites W2566837972 @default.
• W2912757866 cites W2781033923 @default.
• W2912757866 cites W2792805205 @default.
• W2912757866 cites W4211044101 @default.
• W2912757866 cites W4211123396 @default.
• W2912757866 cites W4294216483 @default.
• W2912757866 doi "https://doi.org/10.3389/fphar.2019.00008" @default.
• W2912757866 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6360186" @default.
• W2912757866 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30745869" @default.
• W2912757866 hasPublicationYear "2019" @default.
• W2912757866 type Work @default.
• W2912757866 sameAs 2912757866 @default.
• W2912757866 citedByCount "33" @default.
• W2912757866 countsByYear W29127578662019 @default.
• W2912757866 countsByYear W29127578662020 @default.
• W2912757866 countsByYear W29127578662021 @default.
• W2912757866 countsByYear W29127578662022 @default.
• W2912757866 countsByYear W29127578662023 @default.
• W2912757866 crossrefType "journal-article" @default.
• W2912757866 hasAuthorship W2912757866A5012298648 @default.
• W2912757866 hasAuthorship W2912757866A5022579723 @default.
• W2912757866 hasAuthorship W2912757866A5051874580 @default.
• W2912757866 hasAuthorship W2912757866A5058233829 @default.
• W2912757866 hasAuthorship W2912757866A5068534236 @default.
• W2912757866 hasAuthorship W2912757866A5070028463 @default.
• W2912757866 hasAuthorship W2912757866A5083598360 @default.
• W2912757866 hasAuthorship W2912757866A5085177497 @default.
• W2912757866 hasBestOaLocation W29127578661 @default.
• W2912757866 hasConcept C104317684 @default.
• W2912757866 hasConcept C126322002 @default.
• W2912757866 hasConcept C135763542 @default.
• W2912757866 hasConcept C137183658 @default.
• W2912757866 hasConcept C153209595 @default.
• W2912757866 hasConcept C156957248 @default.
• W2912757866 hasConcept C180754005 @default.
• W2912757866 hasConcept C197934379 @default.
• W2912757866 hasConcept C2779134260 @default.
• W2912757866 hasConcept C2779734285 @default.
• W2912757866 hasConcept C31467283 @default.
• W2912757866 hasConcept C513476851 @default.
• W2912757866 hasConcept C54355233 @default.
• W2912757866 hasConcept C60644358 @default.
• W2912757866 hasConcept C71924100 @default.
• W2912757866 hasConcept C86803240 @default.
• W2912757866 hasConceptScore W2912757866C104317684 @default.
• W2912757866 hasConceptScore W2912757866C126322002 @default.
• W2912757866 hasConceptScore W2912757866C135763542 @default.
• W2912757866 hasConceptScore W2912757866C137183658 @default.
• W2912757866 hasConceptScore W2912757866C153209595 @default.
• W2912757866 hasConceptScore W2912757866C156957248 @default.

• next